ライフサイエンスコーパス: preclinical

1 mission (clinical) and bowel mucosal damage (preclinical).

2 genotoxic agents and have shown single-agent preclinical activity in cancers with high levels of repl

3 hout SCeVD, n = 20), CN with SCeVD (n = 22), preclinical AD (pAD) + mild cognitive impairment (MCI) w

4 Preclinical advances in cell-based, protein replacement

5 ling for baseline biomarker levels, baseline Preclinical Alzheimer Cognitive Composite still signific

6 d tau is detrimental to cognitive decline in preclinical Alzheimer's disease during late middle-age.

7 decline of episodic memory is detectable in preclinical Alzheimer's disease.

8 In summary, proNGF maturation is impaired in preclinical and clinical AD while mature NGF degradation

9 production of circumsporozoite proteins for preclinical and clinical applications in malaria vaccine

10 Preclinical and clinical data suggest that acetyl-CoA ca

11 Current strategies in preclinical and clinical development include adoptive tr

12 metabolic fate of TPPs is critical for their preclinical and clinical development.

13 s 2 (SARS-CoV-2) are being expedited through preclinical and clinical development.

14 acy profile, and present recommendations for preclinical and clinical evaluation of COVID-19 vaccine

15 sed review highlights recent achievements in preclinical and clinical imaging of ER and PR in breast

16 We systematically reviewed the preclinical and clinical literature for each compound, c

17 Contrary to results of preclinical and clinical nonintracerebral hemorrhage stu

18 spectrum of regenerative outcomes, including preclinical and clinical outcomes.

19 eases in the number of cell therapies in the preclinical and clinical phases have prompted the need f

20 A synthesis of preclinical and clinical research identified three neuro

21 These preclinical and clinical results demonstrate that MI ind

22 The disconnect between preclinical and clinical results underscores the imperat

23 pharmacokinetics (PK) and catabolism in both preclinical and clinical settings.

24 Preclinical and clinical studies aiming to broaden the t

25 s on the development of brolucizumab and the preclinical and clinical studies evaluating its efficacy

26 In the last decade, a plethora of preclinical and clinical studies have confirmed the effi

27 Preclinical and clinical studies have demonstrated that

28 signaling and TME, and can inform additional preclinical and clinical studies in RCC.

29 discuss the successes and failures of recent preclinical and clinical studies of TRAIL-induced apopto

30 l-surface targeting of specific therapies in preclinical and clinical studies of various solid tumors

31 ng therapies have recently emerged; however, preclinical and clinical studies revealed a limited ther

32 Longitudinal preclinical and clinical studies suggest that Abeta driv

33 ns, providing a translational bridge between preclinical and clinical studies.

34 and improve cardiovascular function in both preclinical and clinical studies.

35 Comparison with lumasiran preclinical and clinical trial data suggested she has <2

36 nts a review of the most recent and relevant preclinical and clinical trials that have tested ASO the

37 Recent preclinical and early clinical trial data show encouragi

38 Preclinical and epidemiological studies indicate a poten

39 learned with this emerging technology during preclinical and especially clinical studies about biolog

40 Purpose To demonstrate preclinical and first-in-human application of an antibod

41 Consistent across preclinical and human studies, the hippocampus displays

42 ered awareness of memory function across the preclinical and prodromal stages of AD.

43 anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with r

44 nto two tiers based on the robustness of the preclinical, and some clinical, results, in which the to

45 Here, we use mechanistic observations in a preclinical animal model to design an ex vivo platform t

46 asures that can accurately translate between preclinical animal models and clinical human studies.

47 f Cd19 expression, suggesting limitations in preclinical animal models of neurotoxicity.

48 evention and treatment of heart failure in 2 preclinical animal models.

49 ified in this review is largely comprised of preclinical animal studies.

50 at has the potential to provide a predictive preclinical approach for simultaneously predicting drug-

51 ctivated macrophages in synovial tissue in a preclinical arthritic rat model.

52 However, this deficit lacks preclinical assessment tools.

53 Here, we show that in preclinical autoimmunity and established systemic lupus

54 umerous advantages for aligning clinical and preclinical (basic neuroscience) studies of neuropsychia

55 effects of different therapeutic windows for preclinical brain research.

56 hetic biology can provide enabling tools for preclinical cancer models and fosters the potential to i

57 More realistic preclinical cancer models are thought to be provided by

58 ly to become useful additions to traditional preclinical cell culture methods and in vivo animal stud

59 compared to healthy controls to characterize preclinical cerebral changes leading to symptoms.

60 Preclinical clearance data were generated following intr

61 ration and promotes colon tumorigenesis in a preclinical colitis-associated tumor model by upregulati

62 of basal forebrain volume was larger in the preclinical compared with the neurotypical subgroup.

63 In preclinical crescentic GN, delayed myeloperoxidase inhib

64 l significance is still under investigation, preclinical data and histologic evidence demonstrate tha

65 have been suggested as potential treatments, preclinical data from animal models can guide the search

66 Significant preclinical data have emerged from GM-CSF deletion/deple

67 In this study, we present preclinical data on domatinostat's efficacy and mode of

68 Preclinical data on these molecules and their ability to

69 Preclinical data presented here supports the evaluation

70 The clinical and preclinical data suggest that pharmacological inhibition

71 Preclinical data suggested that tafasitamab might act sy

72 In line with its preclinical data, PET imaging resulted in clear visualiz

73 vior of the drug in humans is predicted from preclinical data.

74 ll of these data are relevant in the further preclinical development of the archazolids as well as th

75 This Review focuses on discovery and preclinical development projects and has found, as of 1

76 ve undergone clinical trials, with others in preclinical development, and the targeting of Na(V)1.9,

77 g data package, 20 (AM-6494) was advanced to preclinical development.

78 Both individuals with diabetes and preclinical diabetes models exhibit evidence of a defect

79 l review discusses early clinical successes, preclinical directions, and key aspects that could have

80 ols and is crucial for the evaluation of any preclinical disease model.

81 f non-tumor hemodynamics (e.g. brain), other preclinical disease models (e.g. stroke), vascular-targe

82 lantation and credentials the model as a new preclinical drug discovery platform.

83 ptically clear and an excellent platform for preclinical drug discovery studies.

84 ise for detection of kidney function in both preclinical drug screening and clinical settings.

85 kinetics were dose proportional and exceeded preclinical efficacious levels.

86 s for men advance to clinical trials without preclinical efficacy data, due primarily to a paucity of

87 The strong preclinical efficacy of this potent combination against

88 lize PSMA-positive tumor lesions as shown in preclinical evaluation by small-animal PET studies, orga

89 Here, we report the radiosynthesis and preclinical evaluation of [(68)Ga]Ga-NOTA-folate ((68)Ga

90 ses, we herein report the radiosynthesis and preclinical evaluation of an (18)F-labeled glycosylated

91 in objective of this work was to conduct the preclinical evaluation of LSPD in terms of pharmacokinet

92 We now report the identification and preclinical evaluation of the novel, clinical ATR inhibi

93 this report should facilitate the design of preclinical evaluations for potential DMD therapeutics.

94 duced oto- and nephrotoxicity and compelling preclinical evidence for the potential utility of dopami

95 This study provides preclinical evidence for the use of miR-30c-2*/miR-497 d

96 Together, our findings provide preclinical evidence for using a SHP2 inhibitor as a the

97 though much remains to be done, considerable preclinical evidence is now leading to the initiation of

98 ations for which there is clinical or strong preclinical evidence of a predictive benefit from a spec

99 inical trials using repurposed drugs without preclinical evidence of their in vivo efficacy.

100 Preclinical evidence suggests that iNPWT may also preven

101 Preclinical evidence suggests that the nicotinamide aden

102 emistry and physiology of 2-AG signaling and preclinical evidence supporting a role for this system i

103 These findings provide preclinical evidence that a drug repurposing approach to

104 Preclinical evidence with nilotinib, a US Food and Drug

105 t estimates of clinical trial success rates, preclinical expenditures, and cost of capital.

106 further validate the BPRN model as a robust preclinical experimental platform to address current bar

107 Our preclinical findings demonstrate that SHP2 thus plays a

108 Here, we summarize clinical and preclinical findings of epigenetic alterations in schizo

109 We sought to translate these preclinical findings to humans by examining whether slee

110 However, consistent with preclinical findings, AGER expression correlated with hi

111 Preclinical FS and leishmaniasis are endemic to certain

112 n and peripheral tissue expression of HTT in preclinical HD models.

113 ighlight the ease of their implementation in preclinical IBD research.

114 on without antiretroviral therapy as well as preclinical immunization studies that provide a clear ra

115 Most preclinical immunotherapy studies utilize transplant tum

116 Further preclinical in vivo evaluation of promising single versu

117 therapy, owing in part to a lack of adequate preclinical in vivo models to study this disease.

118 f pathogenesis and are often used to perform preclinical in vivo studies of potential therapeutics.

119 st, leading to high throughput and practical preclinical in vivo therapeutic testing.

120 s of drug response and molecular profiles of preclinical in-vitro cancer cell lines (CCLs) exist for

121 sing human pharmacokinetics informed through preclinical infection systems, and return those findings

122 rth, including before and after the onset of preclinical islet autoimmunity.

123 se for the identification of subjects with a preclinical malignant tumor.

124 ebrovascular abnormalities have emerged as a preclinical manifestation of Alzheimer's disease and fro

125 logically relevant gluten- and HLA-dependent preclinical model exists.

126 and provide a transcriptional dataset and a preclinical model for further investigating SCCB biology

127 infection of rhesus monkeys is an important preclinical model for human immunodeficiency virus type

128 Using a preclinical model of adolescent THC exposure in male rat

129 apy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multiple myeloma.

130 sgenic rats (Fmr1-KO rats) as an alternative preclinical model of FXS.

131 antitumor efficacy of (67)Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare i

132 den while improving intestinal function in a preclinical model of ovarian cancer metastasis.

133 -induced muscle wasting and dysfunction in a preclinical model of pancreatic ductal adenocarcinoma (P

134 Here, we develop a robust preclinical model of PD in adult rats induced by the bra

135 We used a preclinical model of uropathogenic Escherichia coli-indu

136 NHPs can therefore be used as a preclinical model to develop HCV vaccines.

137 After establishment of this preclinical model, a cohort of tumor-bearing mice were i

138 acid nanoparticles (NANPs) using a validated preclinical model, peripheral blood mononuclear cells (P

139 ng the multimammate mouse Mastomys coucha as preclinical model, this is the first study demonstrating

140 ated with changes in the gut microbiota in a preclinical model.

141 mor masses was successfully carried out on a preclinical model.

142 at both oral cancer metastasis and pain in a preclinical model.

143 Utilization of proper preclinical models accelerates development of immunother

144 -2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials.

145 oration (EP) have shown promising results in preclinical models and are evaluated in clinical trials.

146 h 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell res

147 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chroni

148 hanism for resistance to anti-PD1 therapy in preclinical models and in patients with disease progress

149 nergy imbalance, with significant results in preclinical models and more limited results in the clini

150 drug resistance, but most therapy-resistant preclinical models are generated in conditions that lack

151 Thus, reliable and integrated preclinical models are required to elucidate the mechani

152 ators (NAMs) have shown promising results in preclinical models but have so far failed in human clini

153 nsequently, we have characterised a panel of preclinical models for their SSTR2 expression, in vivo g

154 introduce a conceptual framework for use of preclinical models for therapeutic development.

155 tation of hPSC-derived cell populations into preclinical models has generated teratomas (tumors arisi

156 igh-fidelity control of neuronal activity in preclinical models have begun to elucidate the contribut

157 provides insights into the usefulness of the preclinical models in enabling pharmacokinetic optimizat

158 s for HGSC has been hampered by a paucity of preclinical models in which new drugs could be tested fo

159 ived from a traditional Chinese medicine, in preclinical models of asthma.

160 of preventive strategies was demonstrated in preclinical models of colorectal cancer.

161 The imaging readouts can be obtained in both preclinical models of diabetes mellitus and patients wit

162 r (AR) activity that has been established in preclinical models of HCC with the clinical failure of A

163 a roadmap for the development of predictive preclinical models of human DILI.

164 nity provides protection in a large panel of preclinical models of infections.

165 atively improving translational relevance of preclinical models of neuropsychiatric diseases.

166 mechanistically interrogate this network in preclinical models of neuropsychiatric disorders.

167 Preclinical models of psychosis propose that hippocampal

168 hibitors have shown therapeutic potential in preclinical models of psychostimulant abuse.

169 Preclinical models show that Scl-Ab administration prese

170 In chronic GVHD preclinical models that have a pathophysiology distinct

171 Preclinical models that reliably recapitulate the immuno

172 we used N-terminomic proteomic profiling in preclinical models to elucidate the in vivo repertoire o

173 tive neuroprotectants have been evaluated in preclinical models, but not one has entered the clinical

174 In preclinical models, LV unloading reduced the expression

175 In preclinical models, peripherally restricted cannabinoid

176 Using patient samples and preclinical models, we objectively quantified DDX3 and A

177 rly detection and the study of metastasis in preclinical models.

178 glucagon-like peptide-1 receptor agonists in preclinical models.

179 ndamental translational value of the current preclinical models.

180 ccination and should be further evaluated in preclinical models.IMPORTANCE Human cytomegalovirus (HCM

181 hroughout this review is the need to develop preclinical molecular therapies that could ultimately be

182 We analyze data from both preclinical mouse experiments and a clinical trial of FM

183 Our studies in an immunocompetent preclinical mouse model demonstrate TAMs can have a func

184 Here, we investigated the role of PAG1 in a preclinical mouse model of house dust mite (HDM)-induced

185 d-twitch behavior was also augmented in this preclinical mouse model.

186 h opens new perspectives for exploitation of preclinical mouse models of cancer, especially when cons

187 cardiac myocytes and fibroblasts, as well as preclinical mouse models of hypertrophy and heart failur

188 ion and imaging of drug-induced apoptosis in preclinical mouse models, thus creating opportunities fo

189 rate that in vivo depletion of NK cells in a preclinical mouse PD model resulted in exacerbated motor

190 cy in preventing TLR7-induced pathology in a preclinical murine model of psoriasis.

191 The second objective was to evaluate whether preclinical mutation carriers demonstrate unique FTD-rel

192 Preclinical mutation carriers exhibited neuropsychiatric

193 21 preclinical (n = 989 animals) and seven clinical (n = 16

194 Using postmortem human MS tissue, a preclinical nonhuman primate model of MS, and two rodent

195 ry supplements and foods persists, promising preclinical NP research is not consistently translating

196 While contrary to preclinical observations and our a priori hypotheses, th

197 sess response to therapy, and we optimized a preclinical PERCIST paradigm to complement clinical stan

198 The concordance and reproducibility of preclinical PERCIST were maximized at alpha = 0.7 and be

199 Understanding early preclinical perfusion alterations may improve understand

200 espite this pivotal role, standardization of preclinical PET/CT protocols, including CT absorbed dose

201 that bind to dimeric quadruplexes, but their preclinical pharmacological evaluation is limited.

202 predictive of initiation of the prodromal / preclinical phase of LOAD for women in midlife and highl

203 astrocyte activation in the brain during the preclinical phase.

204 The innovative potential of the preclinical pipeline compared with the clinical pipeline

205 t comprehensive information about the global preclinical pipeline is unavailable.

206 nerve tumor progression in NF1 and provided preclinical platforms for testing therapies at each tumo

207 PEG-20k LVR compared to WB and Hextend in a preclinical porcine model of lethal HS, despite decrease

208 mation ability was studied in an established preclinical porcine model of wound biofilm infection.

209 Dosimetry models using preclinical positron emission tomography (PET) data are

210 en and cognitive impairment, suggesting that preclinical/prodromal YAP-dependent neuronal necrosis re

211 Herein, we report the identification and preclinical profile of a lead compound 10, (SPR519) as a

212 Gonda and colleagues provide preclinical proof of concept for a new therapeutic strat

213 EPZ-6438 antitumorigenic action, and provide preclinical proof-of-principle evidence for targeting EZ

214 The aim of this study was to perform a preclinical "proof of concept" study of Bergamot polyphe

215 ormance of CA003, the compound with the best preclinical properties, was assessed in a first patient.

216 agents, we created a series of ATM-deficient preclinical prostate cancer models and tested the impact

217 Such models of preclinical pulmonary hypertension, a disease of the pul

218 both humans with cocaine use disorder and in preclinical relapse models.

219 Preclinical research documents the effects of stress exp

220 h affinity and stability and is suitable for preclinical research in immunocompetent murine models.

221 rd learning are both dopamine-dependent, but preclinical research suggests they depend on different d

222 isease models and from other species used in preclinical research.

223 Promising preclinical results have prompted clinical trials using

224 We have conducted a comprehensive preclinical reverse vaccinology-based vaccine program th

225 In preclinical rodent and rabbit models, we show that this

226 rates were comparable with similar data from preclinical rodent models.

227 exist for many drugs, it is unclear whether preclinical samples can be used to predict CDR of real p

228 enerally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated

229 l investigations and accurate triage, use of preclinical scales for stroke recognition, and deploymen

230 CardioCluster utilization in this preclinical setting establish fundamental insights, layi

231 lly relevant potency shift between human and preclinical species (e.g. murine, dog, macaque) in both

232 of silencing that can persist for months in preclinical species and humans.

233 ve been reported to enhance cognition across preclinical species and may also provide beneficial effe

234 sequence homology of TYK2 between human and preclinical species within the ATP binding site highligh

235 Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engageme

236 cal and neuropathological changes during the preclinical stages (onset approximately 24-30 months of

237 trullinated protein antibodies (ACPA) during preclinical stages of disease and accumulation of hyperc

238 Preclinical studies demonstrate that sleep disruption di

239 Preclinical studies demonstrated that complement promote

240 Preclinical studies describing their discovery and mecha

241 Preclinical studies have consistently demonstrated alter

242 Preclinical studies have demonstrated epithelial ablatio

243 In addition, a large number of preclinical studies have demonstrated that ultrasound al

244 Recent preclinical studies have reenergized this field and prov

245 While preclinical studies have reported improvement of behavio

246 Recent preclinical studies have shown that enhancing NMDA recep

247 However, preclinical studies have shown that JAK or PI3K pathway

248 Preclinical studies have shown that magnetic resonance (

249 Most preclinical studies in animal atherosclerosis models do

250 ith, and mouse models of, cystinosis, and in preclinical studies in cystinotic zebrafish.

251 Preclinical studies indicate that blockade of the alpha5

252 DKN2A tumor suppressor in PDAC, clinical and preclinical studies indicate that pharmacological CDK4/6

253 Preclinical studies indicate that radiotherapy synergize

254 The preclinical studies of 7, including efficacy studies in

255 Evidence from clinical and preclinical studies of both periodontal and periapical l

256 atin-remodeling events have shown promise in preclinical studies of CRPC.

257 Here we review in vitro and preclinical studies of dienone compounds including b-AP1

258 tinence.SIGNIFICANCE STATEMENT There are few preclinical studies of fentanyl relapse, and these studi

259 vo and provide a proof of concept for future preclinical studies of nonsense suppression agents in RT

260 er, a perplexing gap exists between the many preclinical studies reporting infarct size reduction wit

261 Earth-based preclinical studies show space radiation decreases roden

262 Findings from clinical and preclinical studies show that the adolescent brain is pa

263 Preclinical studies show that the dopamine D3 receptor (

264 Preclinical studies suggest epigenetic dysregulation, in

265 These preclinical studies suggest PP(i) modulation as a potent

266 To date, preclinical studies suggest that it is possible to devel

267 Initial preclinical studies that elucidated the biology of the p

268 Lastly, we highlight preclinical studies that hold potential for the treatmen

269 o are unclear, delaying the translation from preclinical studies to clinical trials.

270 ls, establishing the potential for multisite preclinical studies to translate into clinical trials.

271 Preclinical studies using an in vivo mouse model also de

272 level might have an impact on the outcome of preclinical studies with macaque models.

273 uidance and present the results of promising preclinical studies with XPO1 and menin-MLL inhibitors.

274 In preclinical studies, 35 completely inhibited ADO product

275 Based on prior preclinical studies, both 2'-O-methoxyethyl (MOE) with a

276 heart failure, atrial fibrillation, and, in preclinical studies, certain cancers.

277 Preclinical studies, in vivo, and in vitro studies, in c

278 In preclinical studies, intracellular islatravir-triphospha

279 Despite the success in preclinical studies, many mGlu(5) negative allosteric mo

280 ow for high-quality, long-term recordings in preclinical studies, the electrodes are foreign objects

281 In these preclinical studies, we describe ADx-001, an Abeta-targe

282 rowth inhibition in RTK-activated cancers in preclinical studies.

283 unotherapy have shown antitumour activity in preclinical studies.

284 accelerated the progress of immunotherapy in preclinical studies.

285 ve treatment of TNBC and may warrant further preclinical study and potentially future investigation i

286 This preclinical study could have a significant impact for br

287 to any humanized IgG1 mAb biotherapeutic for preclinical study support.

288 Thus, our preclinical study supports intrathecally targeting sTNFa

289 The preclinical study using an in vivo mouse model with orth

290 nation during disease progression and enable preclinical testing of targeted antimigration therapies.

291 l cord glioma and may potentially be used in preclinical therapeutic development programs.

292 ain, in part, the failure of many successful preclinical therapies upon their translation to the clin

293 MAGL inhibitor development transitions from preclinical to clinical and theoretical to practical, th

294 Preclinical treatment of NZB/W F1 mice with an inhibitor

295 Preclinical trials in the model demonstrate synergistic

296 In preclinical trials, the recently developed tracer 2-meth

297 As such, this preclinical work provides awareness for the potential lo

298 Preclinical work suggested that addition of azacitidine

299 Following a large body of preclinical work, promising agents that are entering int

300 ls is moderate compared with results seen in preclinical work.